


11-Ketodihydrotestosterone

Cat. No.:	HY-135794		
CAS No.:	32694-37-4		
Molecular Formula:	C ₁₉ H ₂₈ O ₃		
Molecular Weight:	304.42		
Target:	Androgen Receptor		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (328.49 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.2849 mL	16.4247 mL	32.8493 mL
		5 mM	0.6570 mL	3.2849 mL	6.5699 mL
		10 mM	0.3285 mL	1.6425 mL	3.2849 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (8.21 mM); Suspended solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.21 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	11-Ketodihydrotestosterone (11-KDHT; 5α-Dihydro-11-keto testosterone) is an endogenous steroid and a metabolite of 11β-Hydroxyandrostenedione. 11-Ketodihydrotestosterone is an active androgen and is also a potent androgen receptor (AR) agonist with a K _i of 20.4 nM and an EC ₅₀ of 1.35 nM for human AR. 11-Ketodihydrotestosterone drives gene regulation, protein expression and cell growth in androgen-dependent prostate cancer cells ^{[1][2]} .
IC₅₀ & Target	Ki: 20.4 nM (Human androgen receptor) ^[1] EC50: 1.35 nM (Human androgen receptor) ^[1]

In Vitro

11-Ketodihydrotestosterone (11-KDHT; 1-10 nM; 24 hours; LNCaP and VCaP cells) treatment induces significant cell proliferation^[1].

11-Ketodihydrotestosterone (11-KDHT; 0.1-10 nM; 7-10 days; LNCaP and VCaP cells) treatment results in the significant upregulation of KLK3, TMPRSS2 and FKBP5 in both LNCaP and VCaP cells, with the exception of KLK3 at 1 nM in LNCaP cells^[1].

In PNT2 cells, only 20% of 11 β -hydroxyandrostenedione (11OHA4) and 11 β -hydroxytestosterone (11OHT) are metabolised with the former yielding 11keto-androstenedione (11KA4), 11-Ketodihydrotestosterone (11-KDHT) and 11 β -hydroxy-5 α -androstenedione (11OH-5 α DIONE) and the latter yielding 11OHA4, 11KT and 11-Ketodihydrotestosterone with downstream products <0.03 μ M^[2].

In prostate cancer tissue, C11-oxy C19 metabolites at significantly higher levels than the C19 steroids are detected, with unconjugated 11-Ketodihydrotestosterone, 11KT and 11OHA4 levels ranging between 13 and 37.5 ng/g. Analyses of total steroid levels in plasma show significant levels of 11OHA4 (\approx 230-440 nM), 11KT (\approx 250-390 nM) and 11-Ketodihydrotestosterone (\approx 19 nM)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	LNCaP and VCaP cells
Concentration:	0.1 nM, 1 nM or 10 nM
Incubation Time:	7 days (LNCaP cells) or 10 days (VCaP cells)
Result:	Induced significant cell proliferation.

RT-PCR^[1]

Cell Line:	LNCaP and VCaP cells
Concentration:	1 nM, 10 nM
Incubation Time:	24 hours
Result:	Resulted in the significant upregulation of KLK3, TMPRSS2 and FKBP5 in both LNCaP (Fig 3) and VCaP (Fig 4) cells.

REFERENCES

[1]. Pretorius E, et al. 1-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. PLoS One. 2016 Jul 21;11(7):e0159867.

[2]. du Toit T, et al. Profiling adrenal 11 β -hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11 β -hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J Steroid Biochem Mol Biol. 2017 Feb;166:54-67.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA